Table 1.
Patient demographics and baseline disease characteristics by baseline sNfL low (≤ 9.1 pg/ml) vs. high (> 9.1 pg/ml)
| Characteristics | Low sNfL (N = 146) | High sNfL (N = 138) | All patients (N = 284) [7] |
|---|---|---|---|
| Age, years | 36.1 ± 8.12 | 38.6 ± 9.56 | 37.3 ± 8.92 |
| Sex, female, n (%) | 102 (69.9) | 97 (70.3) | 199 (70.1) |
| Race, white, n (%) | 145 (99.3) | 130 (94.2) | 275 (96.8) |
| Weight, kg | 76.55 ± 17.81 | 70.69 ± 18.55 | 73.70 ± 18.38 |
| BMI, kg/m2 | 26.42 ± 5.65 | 24.58 ± 6.48 | 25.53 ± 6.13 |
| MS duration since first symptom, years | 8.40 ± 7.15 | 10.19 ± 8.28 | 9.27 ± 7.75 |
| No. of relapses in the year before the study | 1.3 ± 0.70 | 1.4 ± 0.73 | 1.3 ± 0.72 |
| No. of relapses in the month 12 to month 24 before the study | 0.9 ± 1.03 | 1.1 ± 2.01 | 1.0 ± 1.58 |
| EDSS score | 2.82 ± 1.32 | 3.08 ± 1.26 | 2.95 ± 1.30 |
| No. of Gd + T1 lesions | 0.5 ± 2.55 | 2.6 ± 6.47 | 1.5 ± 4.97 |
| Patients with Gd + T1 lesions, n (%) | 31 (21.2) | 76 (55.1) | 107 (37.7) |
| Patients with previous DMTs, n (%) | 103 (70.5) | 91 (65.9) | 194 (68.3) |
Data are presented as mean ± SD, unless otherwise specified
BMI body mass index; DMTs disease-modifying therapies; EDSS Expanded Disability Status Scale; Gd + gadolinium enhancing; MS multiple sclerosis; sNfL serum neurofilament light chain